Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma
Clinical Study on the Safety and Efficacy of EBV CAR-T /TCR-T Cells in the Treatment of Recurrent / Refractory EBV Positive Nasopharyngeal Carcinoma
Fudan University
24 participants
Dec 28, 2022
INTERVENTIONAL
Conditions
Summary
This study was a single-arm, open-label, "3 + 3" dose-escalation Exploratory research. The patients were divided into two groups: EBV TCR-T-cell Group and EBV CAR-T-cell group. The EBV CAR-T-treated group received three progressively increasing dose levels (3.0 × 106 cells/kg, 9.0 × 106 cells/kg, 1.5 × 107 cells/kg) of EBV CAR-T-cell therapy; The EBV TCR-T-cell group received three progressively increasing doses (5.0 × 106 cells/kg, 1.5 × 107 cells/kg, 3.0 × 107 cells/kg) of EBV TCR-T-cell therapy.
Eligibility
Inclusion Criteria11
- Voluntary written informed consent;
- Age ≥18 years old, ≤75 years old, male and female;
- Expected survival ≥3 months;
- The Eastern Cooperative Oncology Group (ECOG) physical fitness score was 0-2;
- Ebv-positive nasopharyngeal carcinoma was diagnosed by in situ hybridization with Ebers (Eber-fish) .
- Pathological Paraffin section testing (within 5 years before signing the informed consent form) ;
- At least one measurable lesion according to RECIST v1.1 criteria for solid tumors;
- Recurrent/metastatic nasopharyngeal carcinoma patients who had previously failed second-line or more systemic therapy;
- An apheresis or venous access can be established and there are no other contraindications to blood cell isolation；
- CTCAE 5.0 was lower than grade 1 in the side effects of previous anti-tumor therapy (radiotherapy, chemotherapy, targeted therapy, etc.)
- During the study period and up to 6 months after the end of the administration, fertile subjects -LRB-both male and female) were required to use effective medical contraception. For women of reproductive age, a pregnancy test should be performed within 72 hours before the first dose, and the results were negative.
Exclusion Criteria17
- Active central nervous system metastases (except those that are stable after treatment)；
- HIV positive, HBsAg positive and HBV DNA copy number positive (quantitative detection ≥1000 CPS/ml) , HCV antibody positive and HCV RNA positive;
- Patients with mental or psychological disorders who can not cooperate with the treatment and evaluation of the curative effect;
- Subjects with severe autoimmune disease and long-term use of immunosuppressants;
- Active or uncontrolled infection requiring systemic therapy was present within 14 days prior to enrollment；
- Any unstable systemic disease;
- Complicated with dysfunction of important organs such as lung, brain and kidney.
- Subjects had undergone major surgery or severe trauma within 4 weeks before receiving cell therapy, or were expected to undergo major surgery during the study period.
- Participants received their last dose of radiation or anti-tumor therapy within 4 weeks of receiving the cell therapy.
- Participants had or had had other cancers that were incurable for up to 3 years, except for cervical cancer in situ or skin basal-cell carcinoma, and other cancers that had disease-free survival of more than 5 years.
- Treated with Chimeric antigen receptor t-cell therapy within six months.
- Graft-versus-host disease (GVHD)；
- Subjects who were receiving systemic steroid therapy before screening and who required long-term systemic steroid therapy during treatment as determined by the investigator (with the exception of inhaled or topical use) ; And subjects treated with systemic steroids within 72 hours before cell reinfusion (except for inhalation or topical use) .
- Severe allergies or a history of allergies;
- Subjects requiring anticoagulant therapy;
- Pregnant or lactating women, or a six-month pregnancy plan (for both men and women)；
- Researchers believe there are other reasons not to include people in treatment.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
All subjects were subjected to PK blood sampling as prescribed by the protocol.
Target A positive subjects will receive CAR-T cell therapy.
Target A negative, Target B positive and Target C positive subjects will receive TCR-T cell therapy.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05587543